$25.45
1.80% yesterday
Nasdaq, Sep 18, 10:17 pm CET
ISIN
US60770K1079
Symbol
MRNA

Moderna Stock price

$25.45
-2.64 9.40% 1M
-8.36 24.73% 6M
-16.13 38.79% YTD
-44.41 63.57% 1Y
-102.45 80.10% 3Y
-44.42 63.58% 5Y
+6.85 36.83% 10Y
+6.85 36.83% 20Y
Nasdaq, Closing price Thu, Sep 18 2025
+0.45 1.80%
ISIN
US60770K1079
Symbol
MRNA
Industry

Key metrics

Basic
Market capitalization
$9.9b
Enterprise Value
$4.8b
Net debt
positive
Cash
$5.1b
Shares outstanding
389.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.2 | 5.1
EV/Sales
1.6 | 2.5
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
77.1%
Return on Equity
-32.7%
ROCE
-26.7%
ROIC
-43.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1b | $2.0b
EBITDA
$-2.6b | $-4.0b
EBIT
$-2.8b | $-4.2b
Net Income
$-2.9b | $-3.9b
Free Cash Flow
$-3.5b
Growth (TTM | estimate)
Revenue
-39.1% | -39.5%
EBITDA
31.5% | -23.2%
EBIT
35.1% | -20.5%
Net Income
50.5% | -9.0%
Free Cash Flow
12.0%
Margin (TTM | estimate)
Gross
68.3%
EBITDA
-83.8% | -205.2%
EBIT
-90.5%
Net
-94.3% | -198.2%
Free Cash Flow
-113.7%
More
EPS
$-7.5
FCF per Share
$-9.0
Short interest
21.3%
Employees
6k
Rev per Employee
$560.0k
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Moderna forecast:

4x Buy
13%
19x Hold
63%
7x Sell
23%

Analyst Opinions

30 Analysts have issued a Moderna forecast:

Buy
13%
Hold
63%
Sell
23%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,078 3,078
39% 39%
100%
- Direct Costs 975 975
68% 68%
32%
2,103 2,103
4% 4%
68%
- Selling and Administrative Expenses 1,074 1,074
26% 26%
35%
- Research and Development Expense 3,815 3,815
21% 21%
124%
-2,578 -2,578
31% 31%
-84%
- Depreciation and Amortization 208 208
61% 61%
7%
EBIT (Operating Income) EBIT -2,786 -2,786
35% 35%
-91%
Net Profit -2,903 -2,903
51% 51%
-94%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Neutral
Investors Business Daily
about 19 hours ago
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.
Neutral
Accesswire
3 days ago
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data supporting recent FDA approval of 2025-2026 formula of Spikevax CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenici...
Negative
Forbes
4 days ago
On Friday, MRNA stock dropped 7% following a report from The Washington Post that stated a group of health officials reportedly used the Vaccine Adverse Event Reporting System to link the deaths of 25 children to COVID-19 vaccines. This drop brings the stock's year-to-date decline to almost 45%.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today